2024 چین گوانسیان سٹیل پلیٹ انڈسٹری اوپننگ اپ اور بین الاقوامی پریسیشن پروکیورمنٹ کانفرنس گوانگچوئر کاؤنٹی،شانڈونگ صوبے میں منعقد ہوئی
گوانسیان، چین، 4 جولائی 2024ئ/سنہوا-ایشیانیٹ/– “عالمی تجارت کے لئے شانڈونگ اچھی مصنوعات” کے موضوع کے تحت 2024 چین گوانسیان سٹیل پلیٹ انڈسٹری اوپننگ اپ اور بین الاقوامی پریسیشن پروکیورمنٹ کانفرنس 26 سے 28 جون تک گوانسیان کاؤنٹی میں منعقد ہوئی۔ اسٹیل پلیٹ کی صنعت گوانسیان کاؤنٹی کی ایک منفرد اور مقبول و معیاری ستون صنعت […]
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]